Acumen Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
Acumen Pharmaceuticals R&D Spending Growth & History (ABOS)
Acumen Pharmaceuticals's r&d spending was $104.9M for fiscal 2025.
View full Acumen Pharmaceuticals company overviewAcumen Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $104.9M | $11.1M | +11.82% |
| 2024 | 2024-12-31 | $93.8M | $51.5M | +121.65% |
| 2023 | 2023-12-31 | $42.3M | $10.0M | +30.77% |
| 2022 | 2022-12-31 | $32.4M | $20.1M | +162.99% |
| 2021 | 2021-12-31 | $12.3M | $4.3M | +53.87% |
| 2020 | 2020-12-31 | $8.0M | — | — |
Acumen Pharmaceuticals quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27.8M | −$9.3M | −25.09% |
| Q1 2026 | 2026-03-31 | $16.5M | −$8.8M | −34.76% |
| Q4 2025 | 2025-12-31 | $20.5M | −$14.0M | −40.62% |
| Q3 2025 | 2025-09-30 | $22.0M | −$5.3M | −19.37% |
| Q2 2025 | 2025-06-30 | $37.1M | $17.6M | +90.06% |
| Q1 2025 | 2025-03-31 | $25.3M | $12.8M | +102.96% |
| Q4 2024 | 2024-12-31 | $34.6M | $21.3M | +160.05% |
| Q3 2024 | 2024-09-30 | $27.2M | $16.1M | +143.73% |
| Q2 2024 | 2024-06-30 | $19.5M | $10.4M | +113.87% |
| Q1 2024 | 2024-03-31 | $12.4M | $3.7M | +42.88% |
| Q4 2023 | 2023-12-31 | $13.3M | $2.5M | +23.70% |
| Q3 2023 | 2023-09-30 | $11.2M | $2.9M | +34.54% |
| Q2 2023 | 2023-06-30 | $9.1M | $1.8M | +24.75% |
| Q1 2023 | 2023-03-31 | $8.7M | $2.7M | +45.58% |
| Q4 2022 | 2022-12-31 | $10.7M | $5.1M | +89.42% |
| Q3 2022 | 2022-09-30 | $8.3M | $6.5M | +361.61% |
| Q2 2022 | 2022-06-30 | $7.3M | $5.1M | +224.80% |
| Q1 2022 | 2022-03-31 | $6.0M | $3.4M | +132.16% |
| Q4 2021 | 2021-12-31 | $5.7M | — | — |
| Q3 2021 | 2021-09-30 | $1.8M | −$1.2M | −39.88% |
| Q2 2021 | 2021-06-30 | $2.3M | $327,000 | +16.97% |
| Q1 2021 | 2021-03-31 | $2.6M | — | — |
| Q3 2020 | 2020-09-30 | $3.0M | — | — |
| Q2 2020 | 2020-06-30 | $1.9M | — | — |
Acumen Pharmaceuticals r&d spending trends
Over the last five fiscal years, Acumen Pharmaceuticals's r&d spending increased from $8.0M to $104.9M, a change of $96.9M. The latest reported quarter, Q2 2026, shows $27.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acumen Pharmaceuticals source filings ↗